Gilead paid $5 billion for a Munich biotech whose lead programme was ovarian cancer. Sun Pharma paid $11.75 billion for a portfolio that is almost entirely women’s health. Q1 2026 produced a few significant transactions. FHA’s inaugural capital intelligence report analyses what they signal and where a positioned allocator should be looking next.
March was a consequential month. PwC published a detailed analysis of the women’s health market, making the case plainly
Last week, FemmeHealth Alliance hosted our first webinar of 2026: Women’s Hormonal Health — Why Investors Are Paying Attention. The session brought together investors and ecosystem builders across time zones to explore what is shifting beneath the headlines and what that shift means for capital allocation in women’s health.
Women’s Health Is Now Being Evaluated as Infrastructure As 2026 approaches, women’s health is no longer being evaluated as a
